Clinical trial
Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in…
NCT00232479 · University of Miami, Other · Completed
Key facts
| NCT number | NCT00232479 |
|---|---|
| Title | Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer |
| Official title | Phase II Study of Dose Dense Carboplatin and Taxotere With Herceptin As Primary Systemic Therapy in Breast Cancer |
| Lead sponsor | University of Miami, Other |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | trastuzumab, docetaxel and carboplatin in dose dense regimen |
| Enrollment | 48 |
| Start date | Sep 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Oct 4, 2005 |
| Last update posted | Aug 21, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: